BCDA News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

BC

Mkt Cap

$14.2M

Volume

103.22K

Next Earnings

November 11th

Chart Financials Earnings News About Insider Filings

BioCardia Presents CardiAMP HF II Trial Design at Heart Failure Society of America Annual Scientific MeetingBioCardia announced the presentation of its CardiAMP HF II trial design at the HFSA Annual Scientific Meeting. The trial evaluates high-dose autologous cell therapy for patients with ischemic heart failure with reduced ejection fraction. The FDA has granted category B designation for the CardiAMP system and agreed that the ongoing CardiAMP HF II trial may be sufficient to support FDA approval. BioCardia is advancing regulatory submissions with the FDA and Japan's PMDA.GlobeNewswire Inc. · Oct 7, 2026

BioCardia Announces $4.4 Million FinancingBioCardia completed a capital raise of 3.5 million shares at $1.279 per share, extending cash runway into Q1 2027 and potentially beyond PMDA approval. The company received FDA confirmation that CardiAMP HF II trial may support premarket approval, and obtained Japan PMDA Record of Advice supporting regulatory submission for CardiAMP cell therapy for ischemic heart failure treatment.GlobeNewswire Inc. · Jun 8, 2026

BioCardia and FDA Align on Helix Transendocardial Delivery Catheter Clearance PathwaysBioCardia announced that the FDA identified two regulatory pathways for its Helix Transendocardial Delivery Catheter System, with the FDA's preferred route being simultaneous approval with the CardiAMP cell therapy system. The FDA raised no concerns regarding Helix safety data, device performance, or agent compatibility. An alternative DeNovo pathway was also suggested as a potential route to independent Helix market clearance.GlobeNewswire Inc. · May 8, 2026

BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026BioCardia, Inc. announced it will hold a conference call on March 24, 2026 at 4:30 PM EDT to provide a corporate update and report financial results for the year ended December 31, 2025. The call will include management remarks followed by a Q&A session and will be available via phone and webcast.GlobeNewswire Inc. · Mar 19, 2026

BioCardia Announces Pre-Submission Approval Package for Helix Transendocardial Delivery Catheter Accepted by FDABioCardia announced that the FDA has accepted its pre-submission package for the Helix Transendocardial Delivery Catheter, a minimally invasive device for intramyocardial therapeutic and diagnostic agent delivery. The FDA's Center for Devices and Radiological Health (CDRH) will lead the review in consultation with the Center for Biological Evaluation and Research (CBER). The company expects this approval to support its CardiAMP Cell Therapy program for treating ischemic heart failure.GlobeNewswire Inc. · Mar 17, 2026

BioCardia to Host Q3 2025 Corporate Update and Financial Results Conference Call on November 12, 2025BioCardia will host a conference call on November 12, 2025 at 4:30 PM EDT to discuss Q3 2025 financial results and provide a corporate update, with options for phone and webcast participation.GlobeNewswire Inc. · Nov 6, 2025

BioCardia CEO Peter Altman to Present at the H. C. Wainwright 27th Annual Global Investment Conference in New York City September 8-10, 2025BioCardia's CEO Peter Altman will present a corporate update at the H. C. Wainwright conference, discussing clinical cell therapy programs, regulatory activities, and recent partnerships in cardiovascular therapeutics.GlobeNewswire Inc. · Sep 4, 2025

FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define TreatmentThe FDA has approved a protocol amendment for BioCardia's CardiAMP Heart Failure II Trial, allowing more patients to receive the autologous cell therapy. The amendment incorporates a personalized treatment plan based on a pre-procedural cell population analysis, expected to enhance the clinical experience and market opportunity.GlobeNewswire Inc. · Aug 21, 2024

BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery ApproachBioCardia announces that the USPTO has granted Patent No: 11,986,611 titled “Radial and Transendocardial Delivery Catheter,” with a 2036 expiration date.GlobeNewswire Inc. · Jun 7, 2024

BioCardia Announces Reverse Stock SplitSUNNYVALE, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that, following approval by the Company's stockholders and its Board of Directors, the Company intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 15 pre-split shares. The reverse stock split will become effective at 12:01 a.m. Eastern Daylight Time on Thursday, May 30, 2024. The Company’s common stock will begin trading on a split-adjusted basis when the market opens on Thursday, May 30, 2024. The Company’s common stock and warrants will continue to be traded on The Nasdaq Capital Market under the ticker symbols “BCDA” and “BCDAW,” respectively. The reverse stock split is intended to increase the minimum bid price requirement for continued listing on The Nasdaq Capital Market. The Company, however, cannot assure that the price of its common stock after the reverse stock split will reflect the corresponding split ratio, that the price per share following the effective time will be maintained for any period of time, or that the price will remain above the pre-split trading price.GlobeNewswire Inc. · May 21, 2024

BC

BCDABioCardia, Inc. Common Stock

BCDA

Pay with—

Available Balance0.00

Your PositionYou don't own any BCDA yet.

Related Tickers

Earnings